Sigilon Therapeutics is a clinical stage biotechnology company developing a class of therapeutics and functional cures for patients with chronic diseases. Co.'s product candidates include: SIG-001, which prevents bleeding episodes in patients with moderate-severe to severe Hemophilia A; SIG-005, which treats the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease; SIG-007, which provides continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002, which is designed to replace islet cells for the treatment of Type 1 Diabetes. The SGTX stock yearly return is shown above.
The yearly return on the SGTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|